Overview


Thrombosis is a condition in which blood clots form in the arteries or veins. A clot stops blood flow in the affected location, which can result in major problems such as cardiac infarction, strokes, and atherosclerotic plaque, among others. Deep vein thrombosis is a disorder in which blood clots form in the legs or pelvis, and pulmonary embolism occurs when the clots break off and travel to the lungs. Current medications, on the other hand, have life-threatening adverse effects such cerebral haemorrhages and neurotoxicity. Companies are developing novel therapeutic compounds to improve fibrinolysis conditions in order to overcome the aforementioned issues. For example, Daiichi Sankyo Company, Limited stated that its innovative oral anticoagulant medicine edoxaban has been approved by the European Union to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.

The rise in obesity, myocardial infractions, stroke, pulmonary embolism, and genetically associated disorders are driving the growth of this market throughout the predicted period. However, side-effects generated by present medications are impeding the expansion of blood clot prevention over the anticipated period due to a lack of understanding regarding venous thromboembolism circumstances. Over the forecast period, the market is expected to rise due to the introduction of novel therapeutic medications to prevent blood clots in various blood vessels.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Blood Clot Preventive Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Blood Clot Preventive Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Daiichi Sankyo Company
  • Janssen Pharmaceutical
  • Pfizer Inc.
  • Bayer
  • Boehringer Ingelheim GmbH.
  • Bristol- Meyers Squibb
  • Portola Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Anticoagulants
    • Heparin
    • Warfarin
    • Low Molecular Weight Heparin
      • Enoxaparin
      • Dalteparin
    • Newer drugs
      • Bivalirudin
      • Fondaparinux
      • Lepirudin
      • Rivaroxaban
      • Apixaban
  • Fibrinolytics
    • Streptokinase
    • Urokinase
    • Alteplase
    • Reteplase
    • Tenectlase
  • Anti-Platelet Drugs
    • Aspirin
    • Ticlopidine
    • Clopidogrel
    • Abciximab
    • Eptifibatide

By Route of Administration

  • Oral Route
  • Parenteral Route

By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Mail order Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Blood Clot Preventive Drugs Market By Drug Class, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Blood Clot Preventive Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Blood Clot Preventive Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Blood Clot Preventive Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Blood Clot Preventive Drugs Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anticoagulants
         1.1. Heparin
         1.2. Warfarin
         1.3. Low Molecular Weight Heparin
          1.3.1. Enoxaparin
          1.3.2. Dalteparin
         1.4. Newer drugs
          1.4.1. Bivalirudin
          1.4.2. Fondaparinux
          1.4.3. Lepirudin
          1.4.4. Rivaroxaban
          1.4.5. Apixaban
        2. Fibrinolytics
         2.1. Streptokinase
         2.2. Urokinase
         2.3. Alteplase
         2.4. Reteplase
         2.5. Tenectlase
        3. Anti-Platelet Drugs
         3.1. Aspirin
         3.2. Ticlopidine
         3.3. Clopidogrel
         3.4. Abciximab
         3.5. Eptifibatide

  • 8.   Blood Clot Preventive Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral Route
        2. Parenteral Route

  • 9.   Blood Clot Preventive Drugs Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Mail order Pharmacies

  • 10.   North America Blood Clot Preventive Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Blood Clot Preventive Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Blood Clot Preventive Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Blood Clot Preventive Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Daiichi Sankyo Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Janssen Pharmaceutical
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Boehringer Ingelheim GmbH.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol- Meyers Squibb
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Portola Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients